Cancer Treatment: are treatments that may include surgery, chemotherapy, and radiation therapy. If your cancer is particularly sensitive to radiation therapy or chemotherapy, you may receive one of those therapies as your primary treatment. Adjuvant treatment.
-
Recent advances in multi-omic approaches, including genomics, transcriptomics, and proteomics, enable a more comprehensive description of the tumor. This promises to accelerate the developme...
The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...
APR 25, 2023 | 8:00 AM
C.E. CREDITS
Date: April 25, 2023 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Several promising immunotherapies have emerged in recent decades due to advances in cancer immunology. The paradigm o...
MAR 30, 2023 | 8:00 AM
C.E. CREDITS
Date: March 30, 2023 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CET) Join the Gibco Cell Culture Heroes webinar featuring Heather Beasley, PhD as she presents "SLC25A46 as a Novel Mitoc...
MAR 30, 2023 | 1:00 PM
C.E. CREDITS
The circulating T-cell receptor (TCR) repertoire is a dynamic representation of overall immune responses in an individual. Here we aimed to correlate pre-treatment circulating TCR repertoire...
The circulating T-cell receptor (TCR) repertoire is a dynamic representation of overall immune responses in an individual. Here we aimed to correlate pre-treatment circulating TCR repertoire...
MAR 30, 2023 | 12:25 PM
C.E. CREDITS
Next-generation sequencing can detect multiple driver oncogenes simultaneously, enabling the analysis of limited amounts of biopsied tissue samples. . Druggable driver mutations cover more t...
Next-generation sequencing can detect multiple driver oncogenes simultaneously, enabling the analysis of limited amounts of biopsied tissue samples. . Druggable driver mutations cover more t...
FEB 22, 2023 | 5:30 AM
C.E. CREDITS
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of metabolic disorders affecting 25% of our global population. 20% of NAFLD patients go on to develop Non-alcoholic steatohepatitis (N...